MULTIPLEX MEASURE OF ISOTYPE ANTIGEN RESPONSE

• US 20140031249A1
• Filed: 03/15/2013
• Published: 01/30/2014
• Est. Priority Date: 07/20/2004
• Status: Active Application

• Current Assignee: SQI Diagnostics Systems Inc. (SQI Diagnostics, Inc.)
• Original Assignee: SQI Diagnostics Systems Inc. (SQI Diagnostics, Inc.)
• Inventors: Lea, Peter
• Application Number:
  US13/843,297
• Publication Number:
  US 20140031249A1
• Time in Patent Office: Days
• US Class Current: 506/9
• CPC Class Codes: G01N 2800/102 Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
• CPC Class Codes: G01N 33/54306 Solid-phase reaction mechanisms
• CPC Class Codes: G01N 33/564 for pre-existing immune complex or autoimmune disease , i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
• CPC Class Codes: G01N 33/6854 Immunoglobulins
• CPC Class Codes: G01N 33/686 Anti-idiotype

Abstract

Described are methods for simultaneous detection and quantifying multiple target analytes, including immunoglobulin isotypes and sub-classes, single and multiple protein antibodies within a test sample contained in a single reaction vessel. Such methods use reaction wells as on a multi-well plate, each single well comprising microarrays of calibration spots, each having a predetermined quantity of a target analyte; and capture spots, each having multiple agent antibodies, including isotypes and subclasses that specifically bind the target analytes. The captured analytes and the calibration spots are detected with fluorescently labeled antibodies specific for each different target analyte. Calibration spots generate calibration curves for quantitative determinations of different target analytes. Also described are methods for detecting and quantifying biomarkers, therapeutic proteins and patient derived antibodies; the use of secondary reagents to determine immunoglobulin classes Ig G, A, M, E and sub-classes including IgG1, IgG2, IgG3, IgG4 and IgA. The intensity of each fluorescent signal allows measurement of a specific immune response to a therapeutic protein and associated analytes; interrogates neutralizing effects of patient antibodies on therapeutic proteins, e.g., insulin therapy.

Claims

1. A method for simultaneously detecting and quantifying two or more target analytes in a test sample comprising two or more target analytes, contained in a single reaction vessel, the method comprising:

a) providing a reaction vessel having a microarray printed thereon, the microarray comprising;

i) a first calibration matrix comprising a plurality of first calibration spots, each of the first calibration spots comprising a predetermined amount of a first target analyte, the first target analyte being an antibody isotype or an antibody sub-class,

ii) a second calibration matrix comprising a plurality of second calibration spots, each of the second calibration spots comprising a predetermined amount of a second target analyte, the second target analyte being an antibody isotype or an antibody sub-class

iii) a first capture matrix comprising a plurality of first capture spots, each of the first capture spots comprising a predetermined amount of a first agent that selectively binds to the target analytes, and

iv) a second capture matrix comprising a plurality of second capture spots, each of the second capture spots comprising a predetermined amount of a second agent that selectively binds to the target analytes, and

b) adding a predetermined volume of the test sample to the microarray;

c) simultaneously applying at least two fluorescently labelled antibodies into the same well, each of the at least two fluorescently labelled antibodies being specific for one of the target analytes for selectively binding to one of the target analytes for individual identification and quantification of the target analytes, each of the fluorescently labelled antibodies comprising a different fluorescent dye having emission and excitation spectra which do not overlap with each other;

d) measuring signal intensity values for each fluorescently wavelength for each calibration spot and each capture spot within the microarray;

e) generating calibration curves by fitting a curve to the measured signal intensity values for each of the calibration spots versus a known concentration of the first target analyte and the second target analyte in the calibration spots; and

f) determining the concentration for the first target analyte and the second target analytes bound to the capture spots using the generated calibration curves.

2. The method according to claim 1, wherein a plurality of analytes are simultaneously detected.

3. The method according to claim 2, wherein the reaction vessel is a well of a multi-well plate and wherein each well has the microarray printed therein.

4. The method according to claim 1, wherein the test sample is a biological sample.

5. A method for detecting and quantifying immunoglobulins and/or biomarkers diagnostic for insulin immunogenicity, the method comprising:

a) providing an assay device having a microarray printed thereon, the microarray comprising;

i) a calibration matrix comprising plurality of calibration spots, each calibration spot comprising a predetermined amount of a single immunoglobulin class selected from the group consisting of IgA, IgG, IgM, IgD and IgE or a subclass thereof; and

ii) an analyte capture matrix comprising a plurality of capture spots, each capture spot comprising a predetermined amount of an agent that selectively binds to an immunoglobulin class selected from the group consisting of IgA, IgG, IgM, IgD and IgE or a subclass thereof;

b) applying a predetermined volume of a serum sample to the assay device;

c) applying a first fluorescently labelled antibody that selectively binds to IgA antibodies, a second fluorescently labelled antibody that selectively binds to IgG antibodies, a third fluorescently labelled antibody that selectively binds to IgM antibodies, a fourth fluorescently labelled antibody that selectively binds to IgE antibodies, a fifth fluorescently labelled antibody that selectively binds to IgE antibodies and a sixth fluorescently labelled antibody that selectively binds to respective sub-class antibodies to the assay device, wherein the first, second, third, fourth, fifth and sixth fluorescently labelled antibodies each comprise a different fluorescent dye having emission and excitation spectra which do not overlap with each other;

d) measuring signal intensity values for each fluorescently wavelength for each calibration spot and each capture spot within the microarray;

e) generating calibration curves by fitting a curve to the measured signal intensity values for the each of the calibration spots versus the known concentration of the human IgA, IgG, IgM, IgE, IgD and subclass immunoglobulins; and

f) determining the concentration for each captured analyte using the calibration curves.

6. A method for diagnosing neutralizing antibodies neutralizing therapeutic protein insulin in a subject, the method comprising:

a) providing an assay device having a microarray printed thereon, the microarray comprising;

iii) a calibration matrix comprising plurality of calibration spots, each calibration spot comprising a predetermined amount of a single immunoglobulin class selected from the group consisting of neutralizing factor-IgA, neutralizing factor-IgG, neutralizing factor-IgM, neutralizing factor-IgE, anti-insulin peptide-IgG, anti-insulin peptide-IgA, anti-insulin peptide-IgM and anti-insulin peptide-IgE;

iv) an analyte capture matrix comprising a plurality of capture spots, each capture spot comprising a predetermined amount of an agent that selectively binds to an immunoglobulin class selected from the group consisting of neutralizing factor-IgA, neutralizing factor-IgG, neutralizing factor-IgM, neutralizing factor-IgE, anti-insulin peptide-IgG, anti-insulin peptide-IgA, anti-insulin peptide-IgM and anti-insulin peptide-IgE;

b) applying a predetermined volume of a serum sample to the assay device;

c) applying a first fluorescently labelled antibody that selectively binds to neutralizing factor IgA antibodies, a second fluorescently labelled antibody that selectively binds to neutralizing factor IgG antibodies, a third fluorescently labelled antibody that selectively binds to IgM antibodies, a fourth fluorescently labelled antibody that selectively binds to neutralizing factor IgE antibodies, a fourth fluorescently labelled antibody that selectively binds to neutralizing factor IgM antibodies, a fifth fluorescently labelled antibody that selectively binds to anti-insulin peptide-IgG, a sixth fluorescently labelled antibody that selectively binds to anti-insulin peptide-IgA, a seventh fluorescently labelled antibody that selectively binds to anti-insulin peptide-IgM and an eighth fluorescently labelled antibody that selectively binds to anti-insulin peptide-IgE to the assay device, wherein the first, second, third, fourth, fifth, sixth, seventh and eighth fluorescently labelled antibodies each comprise a different fluorescent dye having emission and excitation spectra which do not overlap with each other;

d) measuring signal intensity values for each fluorescently wavelength for each calibration spot and each capture spot within the microarray;

e) generating calibration curves by fitting a curve to the measured signal intensity values for the each of the calibration spots versus the known concentration of neutralizing factor-IgA, neutralizing factor-IgG, neutralizing factor-IgM, neutralizing factor-IgE, anti-insulin peptide-IgG, anti-insulin peptide-IgA, anti-insulin peptide-IgM and anti-insulin peptide-IgE; and

f) determining the concentration levels of neutralizing factor-IgA, neutralizing factor-IgG, neutralizing factor-IgM, neutralizing factor-IgE and at least one of anti-insulin peptide-IgG, anti-insulin peptide-IgA, anti-insulin peptide-IgM and anti-insulin peptide-IgE in a biological sample, using the calibration curves.

7. A method for simultaneously detecting and quantifying two or more different target analytes in a test sample, the method comprising:

(a) providing a reaction vessel having a microarray printed thereon, the microarray comprising;

i) a calibration matrix comprising, for each of the target analytes, a plurality of calibration spots, each calibration spot comprising a predetermined known amount of a the target analyte in question,

iii) a capture matrix for each of the target analytes, comprising a plurality of capture spots, each capture spot comprising a predetermined amount of a binding agent that selectively binds to the target analytes in question, and

b) applying to the microarray a predetermined volume of the test sample to the microarray;

c) applying to the microarray a fluorescently labelled antibody specific to each of the target analytes, wherein each fluorescently labelled antibody selectively binds to the target analyte in question, and wherein each of the fluorescently labelled antibodies comprises a different fluorescent dye having emission and excitation spectra which do not overlap with each other;

d) measuring signal intensity values for each spot within the microarray;

e) generating a calibration curve for each target analyte by fitting a curve to the measured signal intensity values of each of the calibration spots for the target analyte in question versus the known concentrations of the calibration spots for the target analyte; and

f) determining the concentration for each target analyte using the corresponding calibration curves for the target analyte.

8. The method according to claim 7, wherein the target analytes are proteins.

9. The method according to claim 8, wherein the proteins are antibodies.

10. A method according to claim 7 wherein the step of measuring a signal intensity value for each spot within the microarray is carried out with a signal detector that is used to read one optical channel at a time.

11. A method for detecting and quantifying biomarkers diagnostic for rheumatoid arthritis, wherein the biomarkers comprise two or more target analytes in a serum sample, the method comprising:

a) providing an assay device having a microarray printed thereon, the microarray comprising;

i) a calibration matrix comprising, for each target analyte, a plurality of spots for each target analyte, each spot comprising a predetermined amount of the target analyte, and wherein the target analytes are a human IgA antibody, a human IgG antibody, and a human IgM antibody;

ii) a first analyte capture matrix comprising a plurality of spots, each spot comprising a predetermined amount of rheumatoid factor; and

iii) a second analyte capture matrix comprising a plurality of spots, each spot comprising a predetermined amount of cyclic citrullinated peptide;

b) applying a predetermined volume of the serum sample to the assay device;

c) applying a first fluorescently labelled antibody that selectively binds to IgA antibodies, a second fluorescently labelled antibody that selectively binds to IgG antibodies, and a third fluorescently labelled antibody that selectively binds to IgM antibodies to the assay device, wherein the first, second and third fluorescently labelled antibodies each comprise a different fluorescent dye having emission and excitation spectra which do not overlap with each other;

d) measuring signal intensity values for each spot within the assay device;

e) generating a calibration curve for each of the IgA, IgG and IgM antibodies, by fitting a curve to the measured signal intensity values of the calibration spots for the antibody in question versus the known concentration of the antibody; and

f) determining the concentration for each of captured rheumatoid factor-IgA, rheumatoid factor-IgG, rheumatoid factor-IgM, anti-cyclic citrullinated peptide-IgG, anti-cyclic citrullinated peptide-IgA, and/or anti-cyclic citrullinated peptide-IgM, in the first and second capture matrices, using the calibration curves for each of the IgA, IgG and IgM antibodies;

wherein the detection and quantification of rheumatoid factor antibodies, and

anti-cyclic citrullinated peptide antibodies is diagnostic for a stage of rheumatoid arthritis.

12. The method according to claim 11, further comprising:

diagnosing rheumatoid arthritis in a subject, comprising comparing the measured concentration levels of rheumatoid factor-IgA, rheumatoid factor-IgG, rheumatoid factor-IgM, anti-cyclic citrullinated peptide-IgG, anti-cyclic citrullinated peptide-IgA, and/or anti-cyclic citrullinated peptide-IgM with index normal levels of rheumatoid factor-IgA, rheumatoid factor-IgG, rheumatoid factor-IgM and anti-cyclic citrullinated peptide-IgG, anti-cyclic citrullinated peptide-IgA, and/or anti-cyclic citrullinated peptide-IgM wherein measured concentrations levels which exceed index normal levels is diagnostic for rheumatoid arthritis.

13. The method of claim 12, wherein detection and quantification of predominantly rheumatoid factor-IgM and anti-cyclic citrullinated peptide-IgM antibodies is diagnostic for an early stage of rheumatoid arthritis.

14. The method of claim 12, wherein the detection and quantification of rheumatoid factor-IgA and anti-cyclic citrullinated peptide-IgA antibodies is diagnostic for a transitional stage of rheumatoid arthritis.

15. The method of claim 12, wherein the detection and quantification of rheumatoid factor-IgG and anti-cyclic citrullinated peptide-IgG antibodies is diagnostic for a late stage of rheumatoid arthritis.

16. The method according to claim 11, wherein the step of measuring a signal intensity value for each spot within the microarray is carried out with a signal detector that is used to read one optical channel at a time.

17. A method for simultaneously detecting and quantifying two or more different target analytes in a test sample, the method comprising:

(a) providing a reaction vessel having a microarray printed thereon, the microarray comprising;

a capture matrix for each of the target analytes, comprising a plurality of capture spots, each capture spot comprising a predetermined amount of a binding agent that selectively binds to the target analytes in question, and

b) applying to the microarray a predetermined volume of the test sample to the microarray;

c) applying to the microarray a fluorescently labelled antibody specific to each of the target analytes, wherein each fluorescently labelled antibody selectively binds to the target analyte in question, and wherein each of the fluorescently labelled antibodies comprises a different fluorescent dye having emission and excitation spectra which do not overlap with each other;

d) measuring signal intensity values for each spot within the microarray;

e) determining the concentration for each target analyte with reference to an external standard.

18. The method according to claim 17 wherein the method is simultaneously carried out in multiple individual wells of a multiplex assay device, wherein each individual well detects multiple different antibody sub-classes and isotypes.